Life Sciences Tools and Services
Company Overview of EMD Millipore Corporation
EMD Millipore Corporation provides solutions and services for the research, development, and production of biotechnology and pharmaceutical drug therapies. The company offers analytics and sample preparation products, such as chromolith products, test strips, reference materials, and disinfection controls; biopharmaceutical manufacturing products, such as depth filters, prepacked chromatography columns, resins, and ultrafiltration cassettes; industrial microbiology products that include EZ-products, microbial air monitoring systems, microbial contamination detectors, and granulated media pouches; and IVD/OEM materials and reagents, including bulk and custom antibodies, blood typing monoclona...
290 Concord Road
Billerica, MA 01821-7037
Founded in 1954
Key Executives for EMD Millipore Corporation
Chief Executive Officer, President and Chief Executive Officer of Milliporesigma
Head of Legal and General Counsel
Head of Global Research & Applied Solutions Commercial Area
Head of Commercial Operations - Americas
Head of Global Process Solutions Commercial Area
Compensation as of Fiscal Year 2016.
EMD Millipore Corporation Key Developments
EMD Millipore Introduces Parteck® SRP 80 Excipient for Sustained-Release Oral Solid Dose Formulations
Oct 26 15
EMD Millipore introduced Parteck® SRP 80, a new functional excipient for oral sustained-release formulations. Parteck® SRP 80 is a polyvinyl alcohol (PVA) based excipient specifically designed for modified-release applications, for optimization of pharmacokinetics and pharmacodynamics as well as the bioavailability of actives. The new excipient is fully synthetic, ensuring batch-to-batch and performance consistency and facilitating quality by design (QbD) and validation processes. Suitable for direct compression processes, Parteck® SRP 80 allows for fast, easy and efficient formulation development as well as production processes. Parteck® SRP 80 is compliant with European Pharmacopoeia (Ph. Eur.), United States Pharmacopoeia (USP) and Japanese Pharmacopoeia Excipients (JPE) and will be part of EMD Millipore's Emprove® program to facilitate regulatory filing and registration processes.
Merck Millipore to Provide Provantage End-to-End Solution for Development and Manufacture of Biosimilars Under Strategic Alliance with Turgut Ilac
Oct 22 15
Merck Millipore has entered into a strategic alliance with Turgut Ilaç and will provide their Provantage End-to-End services for development and manufacturing of biologics. Merck Millipore's Provantage End-to-End solution is a comprehensive suite of products and services enabling biopharmaceutical companies to accelerate progress of molecules into the clinic and toward commercialization. The turnkey package includes process development, cGMP manufacturing, facility design, equipment for pilot plant production, process and equipment training, technology transfer, equipment qualification and set-up for commercialization. Under this multi-year agreement with Turgut Ilaç, Merck Millipore will provide process development, equipment for a pilot facility, cGMP manufacturing, facility design and ultimately, technology transfer of the manufacturing process to Turgut's facility for commerical production. Use of an identical template in both pilot and commercial scale facilitates technology transfer. Phase one of the agreement will focus on monoclonal antibody biosimilars for non-small cell lung carcinoma and rheumatoid arthritis, the first molecules of Turgut's biosimilar pipeline that will be supported by Merck Millipore under this strategic relationship. Financial terms were not disclosed.
EMD Millipore Adds Protein Pegylation to Portfolio of Services for Biopharmaceutical Industry through Collaboration with celares GmbH
Jul 27 15
EMD Millipore announced a collaboration with celares GmbH to provide pegylation services to customers developing protein-based therapeutics and biosimilars. The new service offering enabled by the collaboration includes feasibility studies, process and analytical development, and scale-up from milligram to gram quantities required for pilot and subsequent commercial scale. Pegylation, the attachment of polyethylene glycol to a molecule, can significantly improve the pharmacological and physicochemical properties of peptide and protein therapeutics and reduce side effects. This well-recognized delivery system for biologics can enhance protein stability, bioavailability and solubility, overcoming common challenges in the development of these therapeutics. The new services will leverage EMD Millipore's broad range of functionalized PEG products of different molecular weight and activation chemistry, as well as buffers, solvents and excipients, unit operations employed during the pegylation process and subsequent purification including tangential and normal flow filtration and chromatography.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|